|
|
|
|
Medical News: TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing In Diabetic Foot Infection Met Primary Endpoints
TaiGen Biotechnology Co., Ltd.announced the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a...
|
|
|
TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing In Diabetic Foot Infection Met Primary Endpoin
TaiGen Biotechnology Co., Ltd.announced the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a...
|
|
|
Preventing gastric cancer with antibiotics
Infection by the H.pylori bacterium can approach 100% in developing countries. Most infected people do not have symptoms, but many develop problems including stomach ulcers. pylori causes more than 90% of all duodenal ulcers and can also contribute...
|
|
|
Telaprevir Coinfection Study Open - Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2
This study is currently recruiting participants.Verified by Vertex Pharmaceuticals Incorporated, March 2010 Purpose The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in...
|
|
|
TaiGen Biotechnology Announces Nemonoxacin (TG-8738
TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd.announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical...
|
|
|
Research and Markets: Systemic Fungal Infection Therapeutics Market in Australia
Let the jobs come to you!Research and Markets (http://www.researchandmarkets.com/research/3559e8/systemic_fungal_in) has announced the addition of Frost & Sullivan's new report '' to their offering! This research service aims to provide an update on...
|
|
|
Swine flu kills two as death toll hits 24
TWO men have died in the first recorded deaths from swine flu so far this year.It brings to 24 the total number of people who have died from the virus in Ireland. The men, who were both from the east of the country and had underlying medical conditions,...
|
|
|
Swine flu kills two as death toll hits 24
TWO men have died in the first recorded deaths from swine flu so far this year.It brings to 24 the total number of people who have died from the virus in Ireland. The men, who were both from the east of the country and had underlying medical conditions,...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D.
|
|
|
TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoin
Promising Anti-MRSA Activity and Excellent Pharmacokinetic Profile Demonstrated in a Phase II Proof of Concept trial TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd.announced today the Phase II trial of nemonoxacin (TG-873870) in...
|
|
|
Total Parenteral Nutrition Linked With Fungal Infection of Ventricular Assist Devices
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
CAMBRIDGE, Mass.(BUSINESS WIRE) Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil....
|
|
|
Integrated care pilot programme: ensuring people with dementia receive joined up care
The government is piloting several models of integrated working in health and social care.A nurse led pilot improved support for older people with dementia Please sign in or register Registration is required to read the entire article and to gain access to...
|
|
|
Total Parenteral Nutrition Linked With Fungal Infection of Ventricular Assist Devices
_ Total Parenteral Nutrition Linked With Fungal Infection of Ventricular Assist Devices.
|
|
|
Preventing gastric cancer with antibiotics
Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer.In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief Executive Officer and...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief Executive Officer and...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D.
|
|
|
Preventing gastric cancer with antibiotics
Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer.In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori...
|
|
|
Can H. pylori Infections Be Eradicated?
Helicobacter pylori, a bacterium found in about 50 percent of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer.In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H.
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D.
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
(BUSINESS WIRE) ----Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
(BUSINESS WIRE) ----Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
CAMBRIDGE, Mass.Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief...
|
|
|
Antibiotics lower risk of developing gastric cancer
Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer.In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori...
|
